Replies to post #137628 on Biotech Values

[ariadndndough]

Dendreon Announces New Time for Fourth Quarter and Year-End Financial Results Conference Call and Webcast Presentations at Upcoming Conferences
Call to be held on Monday, February 27, 2012, at 9:00 a.m. ET


......
SEATTLE--(BUSINESS WIRE)--

February 22, 2012 – Dendreon Corporation (Nasdaq: DNDN - News) today announced that management will host a conference call on Monday, February 27, 2012, at 9:00 a.m. ET to review fourth quarter and year-end financial results. This conference call was previously scheduled at 4:30 p.m. ET on the same date.

Access to the discussion may be obtained as follows:

Time: 9:00 a.m. ET / 6:00 a.m. PT
Date: February 27, 2012
Dial-in: 1-877-548-9590 (domestic) or [phone] (international);
conference pass code: 46511476
Webcast: www.dendreon.com (homepage and investor relations section)


A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-800-585-8367 or [phone] for international callers; the conference ID number is 46511476. The replay will be available from 12:00 p.m. ET on Monday, February 27, until 11:59 p.m. ET on Monday, March 5. In addition, the webcast will be archived for on-demand listening for 90 days at www.dendreon.com.

In addition, Dendreon Corporation also announced that management will present at the following conferences:

•RBC Capital Markets’ Healthcare Conference in New York City, on February 28, 2012, at 3:35 p.m. ET
•Citi 2012 Global Healthcare Conference in New York City, on February 29, 2012, at 2:00 p.m. ET
The presentations will be audio webcast live and available for replay from Dendreon’s website, www.dendreon.com. If you are unable to listen to the live webcasts, they will be archived on the site following the presentation. To access the replays, go to the Investor Relations section of the website.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target

[oc631]

If this is an example of the accuracy of Lee's picks, I will not be following him.

I can't help but feel it's the panel that's out-of-whack here considering the drug's safety profile and the lopsided vote. Politics and group-think may have overrode science. Everyone agreed before the meeting the vote should have been close.

BTW I thought the drug eventually deserved the blessing of the advisory panel. I question whether the data yesterday was sufficient to honestly answer the concerns raised when Qnexa was rejected the first time around. VVUS appears to have done a good job finding data to counterbalance CV concerns.